Krueppel-Like Factor 4 Expression in Phagocytes Regulates Early Inflammatory Response and Disease Severity in

Toni Herta1, Aritra Bhattacharyya1, Maciej Rosolowski2

  • 1Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Frontiers in Immunology
|September 30, 2021
PubMed

Insights

Krueppel-like factor 4 (KLF4) in myeloid cells drives inflammation in bacterial pneumonia. Reduced KLF4 impairs immune response, worsening disease, while higher levels in patients indicate better outcomes.

Area of Science:

  • Immunology
  • Microbiology
  • Pathology

Background:

  • Krueppel-like factor 4 (KLF4) influences immune responses.
  • Streptococcus pneumoniae is a primary cause of community-acquired pneumonia (CAP).
  • The role of KLF4 in myeloid cells during pneumococcal pneumonia requires elucidation.

Purpose of the Study:

  • To investigate KLF4's impact on myeloid cell inflammatory response and disease severity in pneumococcal pneumonia.
  • To assess KLF4 expression in a mouse model and human CAP patients.

Main Methods:

  • Generated myeloid-specific KLF4 knockout mice.
  • Infected mice with Streptococcus pneumoniae.
  • Analyzed inflammatory cytokines (pro-inflammatory and IL-10) in bronchoalveolar lavage fluid and plasma.
  • Assessed bacterial clearance, lung damage, and survival rates.
  • Correlated KLF4 gene expression with clinical presentation (SOFA score), IL-10 levels, and outcomes in hospitalized CAP patients.

Main Results:

  • Myeloid KLF4 knockout mice showed insufficient early immune response, with reduced pro-inflammatory cytokines and increased IL-10.
  • Impaired bacterial clearance, increased bacteremia, lung damage, and reduced survival were observed in knockout mice.
  • Higher KLF4 expression in CAP patients correlated with milder disease (lower SOFA score), lower IL-10, shorter hospital stay, and reduced mortality.

Conclusions:

  • KLF4 in macrophages and polymorphonuclear neutrophils (PMNs) is crucial for regulating the early pro-inflammatory immune response in pneumococcal pneumonia.
  • KLF4 acts as a key regulator of disease severity.
  • KLF4 represents a potential therapeutic target for pneumococcal pneumonia.